Biological variation of intact fibroblast growth factor 23 measured on a fully automated chemiluminescent platform

Annals of Clinical Biochemistry
Antonín JaborJanka Franeková

Abstract

Fibroblast growth factor 23 (FGF23), a potent regulator of phosphate and vitamin D metabolism, is a new biomarker of kidney, bone and cardiovascular disorders. The aim of this study was to assess the biological variation of intact fibroblast growth factor 23 (iFGF23). The within-subject (CVI) and between-subject (CVG) biological variations were assessed in 14 healthy volunteers in a six-week protocol (seven samples). Imprecision (CVA) was assessed by duplicate measurements and the EP15-A2 protocol. Intact FGF23 was measured using a fully automated chemiluminescent assay (Liaison XL, DiaSorin S.p.A., Saluggia, Italy). Two methods with different sensitivities to non-Gaussian distribution were used to estimate the CVI, SD ANOVA and CV ANOVA methods. We calculated the index of individuality (II) and reference change values. Depending on the statistical method used, the CVI and CVA were 14.2 and 3.7% (SD ANOVA) or 12.5 and 3.9% (CV ANOVA), respectively. The corresponding reference change values were 40.5 and 36.4%, respectively. The CVG was 13.4% (SD ANOVA was the only option), and the total imprecision (EP15-A2) was less than 7%. The measurement of iFGF23 demonstrated a CVA less than 4% during the experimental estimation of biologi...Continue Reading

References

Jul 29, 2006·Clinical Chemistry·M Rebecca FokkemaJoachim Moecks
Jan 25, 2008·Journal of the American Society of Nephrology : JASN·Tamara IsakovaMyles Wolf
Oct 30, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Marc G VervloetPiet M ter Wee
Mar 3, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Tamara IsakovaMyles Wolf
Jun 13, 2012·The Journal of Clinical Endocrinology and Metabolism·Edward R SmithStephen G Holt
Jan 30, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Etienne CavalierOlivier Moranne
Nov 26, 2013·Annals of Clinical Biochemistry·Edward R SmithStephen G Holt
May 29, 2014·Current Opinion in Nephrology and Hypertension·Myles Wolf, Kenneth E White
Feb 27, 2015·Clinical Chemistry and Laboratory Medicine : CCLM·Callum G Fraser
Feb 10, 2016·Critical Reviews in Clinical Laboratory Sciences·Federica Braga, Mauro Panteghini
Aug 11, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Ferruccio CeriottiMauro Panteghini
Aug 2, 2017·Calcified Tissue International·Jean-Claude SouberbielleEtienne Cavalier
Oct 14, 2017·The Journal of Clinical Endocrinology and Metabolism·Elisa Holmlund-SuilaOuti Mäkitie
Dec 10, 2017·Clinical Chemistry·Aasne K AarsandUNKNOWN European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation and Task and Finish
May 1, 2017·The Journal of Applied Laboratory Medicine·Salena CuiDavid E Leaf

❮ Previous
Next ❯

Citations

Jun 22, 2021·Clinica Chimica Acta; International Journal of Clinical Chemistry·Antonín JaborJanka Franeková

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay
ELISA

Software Mentioned

Excel
R

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.